Scientific publications

April 2022
Intratumoral CD40 Agonist Sotigalimab (APX005M) with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in Metastatic Melanoma
AACR Presentation
March 2022
Elucidating Factors of Therapeutic Response to Immunotherapy Combined with Neoadjuvant Radiation Therapy for Rectal Cancer
Keystone Poster
November 2021
Innate: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer to Elucidate Local and Systemic Therapeutic Response
SITC Poster
November 2021
Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
SITC Poster
November 2021
Multi-Omic Multi-Parameter Circulating Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Activation Signatures in the Pancreatic Cancer Setting
SITC Poster
June 2021
Gemcitabine and nab-Paclitaxel ± Nivolumab ± CD40 Agonistic Monoclonal Antibody Sotigalimab (APX005M) in Participants with Untreated Metastatic Pancreatic Adenocarcinoma: Phase 2 Final Results
ASCO Poster
December 2020
First in Pediatrics Phase 1 Study Of CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors
ISPNO Presentation
February 2020
A Phase II Trial with a Safety Lead-in to Evaluate the Addition of APX005M, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Patients with Advanced Sarcoma
ASCO SITC Poster
September 2019
Intratumoral CD40 Agonist (APX005M) in Combination with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in CPI Treatment Naïve Metastatic Melanoma
CICON Poster
April 2019
Phase 1b/2 Study of CD40 Agonistic Antibody APX005M in Combination with Nivolumab (Nivo) in Subjects with Metastatic Melanoma (M) and Subjects with Non-Small Cell Lung Cancer (NSCLC)
AACR Poster